Literature DB >> 17344916

Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature.

K Nishii, R Nanbu, F Lorenzo V, F Monma, K Kato, H Ryuu, N Katayama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17344916     DOI： 10.1038/sj.leu.2404626

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.

Authors:  J M Raya; L Arenillas; A Domingo; B Bellosillo; G Gutiérrez; E Luño; M A Piñán; M Barbón; M L Pérez-Sirvent; M J Muruzábal; L Yánez; L García; A Lemes; J T Navarro; A Elosegi; M A Cortés; A Villegas; M A Durán; M Ardanaz; L Florensa
Journal:  Int J Hematol       Date:  2008-09-27       Impact factor: 2.490

Review 2.  Whole genome scanning as a cytogenetic tool in hematologic malignancies.

Authors:  Jaroslaw P Maciejewski; Ghulam J Mufti
Journal:  Blood       Date:  2008-05-27       Impact factor: 22.113

3.  Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.

Authors:  Bella S Guerrouahen; Muneyoshi Futami; Christos Vaklavas; Jukka Kanerva; Zakary L Whichard; Kenechi Nwawka; Elisabeth G Blanchard; Francis Y Lee; Lisa J Robinson; Robert Arceci; Steven M Kornblau; Eric Wieder; Yvon E Cayre; Seth J Corey
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

4.  Changing histopathological diagnostics by genome-based tumor classification.

Authors:  Michael Kloth; Reinhard Buettner
Journal:  Genes (Basel)       Date:  2014-05-28       Impact factor: 4.096
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.